TNF: A moonlighting protein at the interface between cancer and infection

H. Hundsberger, A. Verin, C. Wiesner, M. Pflüger, A. Dulebo, W. Schütt, I. Lasters, D.N. Männel, A. Wendel, R. Lucas

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung


The remarkable ability of TNF, especially in combination with Interferon-gamma or melphalan, to inhibit the growth of malignant tumor cells is so far unmatched. Unfortunately, its high systemic toxicity and hepatotoxicity prevent its systemic use in cancer patients. An elegant manner to circumvent this problem is the isolated limb and liver perfusion for the treatment of melanoma, soft tissue sarcoma and liver tumors, respectively, although the latter method can lead to a reversible hepatotoxicity. In order to allow also the treatment of other cancers with TNF, new strategies have to be developed that aim at sensitizing tumor cells to TNF and at reducing its systemic and liver toxicity, without losing its antitumor efficiency. Moreover, the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites, could be useful in reducing cancer treatment-related pulmonary edema formation. This review will discuss some recent developments in these areas, which can lead to a renewed interest in TNF for the systemic treatment of cancer.
Seiten (von - bis)5374-5386
FachzeitschriftFrontiers in Bioscience
PublikationsstatusVeröffentlicht - 1 Mai 2008


Untersuchen Sie die Forschungsthemen von „TNF: A moonlighting protein at the interface between cancer and infection“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren